- Home
- ICCC vs MRSN Comparison
ICCC vs MRSN Comparison
Compare ICCC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- MRSN
- Stock Information
- Founded
- ICCC 1982
- MRSN 2001
- Country
- ICCC United States
- MRSN United States
- Employees
- ICCC N/A
- MRSN N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- MRSN Health Care
- Exchange
- ICCC Nasdaq
- MRSN Nasdaq
- Market Cap
- ICCC 55.5M
- MRSN 47.1M
- IPO Year
- ICCC 1987
- MRSN 2017
- Fundamental
- Price
- ICCC $6.16
- MRSN $10.23
- Analyst Decision
- ICCC
- MRSN Strong Buy
- Analyst Count
- ICCC 0
- MRSN 3
- Target Price
- ICCC N/A
- MRSN $33.00
- AVG Volume (30 Days)
- ICCC 19.4K
- MRSN 69.1K
- Earning Date
- ICCC 11-13-2025
- MRSN 11-12-2025
- Dividend Yield
- ICCC N/A
- MRSN N/A
- EPS Growth
- ICCC N/A
- MRSN N/A
- EPS
- ICCC 0.20
- MRSN N/A
- Revenue
- ICCC $28,274,756.00
- MRSN $34,769,000.00
- Revenue This Year
- ICCC N/A
- MRSN N/A
- Revenue Next Year
- ICCC N/A
- MRSN N/A
- P/E Ratio
- ICCC $31.10
- MRSN N/A
- Revenue Growth
- ICCC 21.75
- MRSN 16.14
- 52 Week Low
- ICCC $3.38
- MRSN $5.21
- 52 Week High
- ICCC $7.60
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- ICCC 46.17
- MRSN 62.25
- Support Level
- ICCC $6.06
- MRSN $8.76
- Resistance Level
- ICCC $6.75
- MRSN $10.64
- Average True Range (ATR)
- ICCC 0.36
- MRSN 0.78
- MACD
- ICCC -0.04
- MRSN -0.03
- Stochastic Oscillator
- ICCC 15.31
- MRSN 64.32
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.